In this discussion case, parents must decide whether or not to enroll their sons in an experimental treatment program designed to alleviate the symptoms of muscular dystrophy. The case explores the genetics and physiology of the disease, FDA regulations surrounding the treatment, and the role that money plays in scientific research.